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Abstract
Background: The mapping of complex diseases is one of the most important problems in human
genetics today. The rapid development of technology for genetic research has led to the discovery
of millions of polymorphisms across the human genome, making it possible to conduct genome-
wide association studies with hundreds of thousands of markers. Given the large number of
markers to be tested in such studies, a two-stage strategy may be a reasonable and powerful
approach: in the first stage, a small subset of promising loci is identified using single-locus testing,
and, in the second stage, multi-locus methods are used while taking into account the loci selected
in the first stage. In this report, we investigate and compare two possible two-stage strategies for
genome-wide association studies: a conditional approach and a simultaneous approach.
Results: We investigate the power of both the conditional and the simultaneous approach to
detect the disease loci for a range of two-locus disease models in a case-control study design. Our
results suggest that, overall, the conditional approach is more robust and more powerful than the
simultaneous approach; the conditional approach can greatly outperform the simultaneous
approach when one of the two disease loci has weak marginal effect, but interacts strongly with the
other, stronger locus (easily detectable using single-locus methods in the first stage).
Conclusion: Genome-wide association studies hold the promise of finding new genes implicated
in complex diseases. Two-stage strategies are likely to be employed in these large-scale studies.
Therefore we compared two natural two-stage approaches: the conditional approach and the
simultaneous approach. Our power studies suggest that, when doing genome-wide association
studies, a two-stage conditional approach is likely to be more powerful than a two-stage
simultaneous approach.
Background
The mapping of complex diseases is one of the most
important problems in human genetics today. The rapid
development of technology has led to the discovery of
millions of polymorphisms across the human genome,
making it possible to conduct genome-wide association
studies with hundreds of thousands of markers.
The single-locus approach to mapping complex traits eval-
uates the marginal effect at each marker in turn, thereby
ignoring potentially useful gene-gene interaction effects.
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Alternative approaches, that take into account both mar-
ginal and interactive effects, may offer increased power,
especially when disease genes have only moderate mar-
ginal effect, but work together (interact) in the manifesta-
tion of a disease [1]. A natural strategy when dealing with
a large number of markers is a two-stage method: in the
first stage, a single-locus approach is used to select prom-
ising markers by employing a liberal significance crite-
rion; in the second stage, multi-locus approaches that
capture both marginal and interaction effects are used to
discover loci at a stringent significance level.
Several promising two-stage approaches have recently
been proposed in the literature [2,3]. In this report, our
goal is to investigate and compare two possible two-stage
strategies. The first one was used in the paper by Marchini
et al. [2]. That method is based on first selecting loci at a
liberal significance level and subsequently testing all the
pairwise combinations of the loci selected in the first
stage. We will refer to this as the simultaneous method.
The second strategy is the so-called conditional approach
(as suggested also by Daly and Altschuler [4]) frequently
used in genetic studies nowadays. Namely, a single-locus
screening is performed in the first stage to select loci at a
more stringent level, and in the second stage pairwise
combinations between the selected loci and the initial set
of loci are being analyzed. We use simulation to address
the following two questions: first, what is the optimal cut-
off (the significance level) for each method to use in the
first stage in order to obtain the highest power to detect
both disease loci at a genome-wide error level of at most
0.05, and second, which of the two strategies mentioned
above performs better.
Results and discussion
For power computation we use an analytical approach:
the "exemplary data" approach of Longmate[5]. The
exemplary data approach provides a general method of
estimating the power of likelihood-ratio tests in complex
disease models. In this approach a disease model is speci-
fied with the conditional penetrance matrix, given each
configuration of risk genotypes, and the joint distribution
of risk genotypes at the disease loci. Then an exemplary
data set is generated that represents the expected data
under the sampling design. The exemplary data set is then
analyzed, computing any desired likelihood-ratio test.
The likelihood-ratio can be used to compute the power of
the same test when applied to data sets simulated under
the same scenario (for details see [5]).
We simulate case-control data under several epistatic
models: two-locus threshold, two-locus multiplicative,
and two-locus missing lethal genotype. In the two-locus
threshold model, the odds of disease have a baseline value
(α) unless a disease allele is present at each locus. Once
this threshold is reached, the odds of disease increase to
α(1 + θ). The missing lethal genotype disease model is
similar to a threshold model, in the sense that a minimum
number of disease alleles are required from both loci.
However if the disease is lethal, all individuals carrying a
large number of disease alleles disappear from the popu-
lation. And for the multiplicative models, the odds of dis-
ease increase multiplicatively both within and between
genotypes once there is at least one disease allele at each
disease locus. Odds of disease for these models are given
in Tables 1, 2, 3.
The minor allele frequency (MAF) at each disease locus is
chosen from {0.05, 0.2, 0.5}, α = 0.05 and the interaction
parameter θ ∈ {1.5, 2.5}. We simulate n = 1000 cases and
n = 1000 controls and 300,000 markers. Two of the mark-
ers are the disease loci. The markers are not linked among
themselves (i.e. they are independent genetic loci).
We compute the power to detect both disease loci as a
function of the cutoff used in the first stage for each of the
two methods (simultaneous and conditional) (details
about these power computations are given in the Methods
Section). The overall Type 1 error is at most 0.05 (using a
Bonferroni correction to account for multiple testing).
The results are presented in Figures 1, 2, 3, 4, 5, 6.
For the conditional approach, a more stringent cutoff can
be used in the first stage (in our simulated examples 10-5
or 10-4), whereas for the simultaneous approach a more
liberal cutoff (for example 10-1) is essential.
In terms of power, the conditional approach performs
generally better (we assume the optimal cutoff has been
chosen for each method). This is especially true when the
Table 1: Threshold Model. Odds of disease for the threshold disease model.
Model 1
bb Bb BB
aa ααα
Aa αα (1 + θ) α(1 + θ)
AA αα  (1 + θ) α(1 + θ)BMC Genetics 2006, 7:39 http://www.biomedcentral.com/1471-2156/7/39
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allele frequencies at the disease loci differ, or more gener-
ally when the effects at the interacting disease loci are not
equal. For example, the threshold disease model when
MAF = (0.05,0.5) in Figure 2. Also the missing lethal gen-
otype disease model illustrates very well the situation
where one disease locus of mild marginal effect is detected
using the conditional approach due to the interaction
with another disease locus with stronger marginal effect.
If the disease loci have approximately the same impor-
tance, the two approaches perform similarly. We have per-
formed power computations also on a three-locus
threshold model and report similar results (Figures 7, 8).
Note
For the conditional approach, for the two-locus disease
models that we have simulated, there seems to be no sig-
nificant loss in power when one uses a less stringent cutoff
in Stage 1, in spite of the use of the Bonferroni correction
and the increase in the number of tests performed as the
threshold in the first stage becomes more liberal. This
phenomenon can be explained in part by our conservative
correction of the error probability for this type of two-
stage (sequential) methods (see Section Methods). In fact
for the three-locus threshold model, the power does
decrease as the significance cutoff in Stage 1 becomes less
stringent (Figures 7, 8). In a real situation, one may want
to use more sophisticated methods to control for the Type
1 error (e.g. resampling methods).
Also we mention that in all three disease models that we
have simulated, there is some marginal effect at one or all
disease loci. If none of the disease loci has any marginal
effect, then only the exhaustive approach (all pair-wise
interactions) has a chance to detect those. However this
approach has real drawbacks: it is computationally inten-
sive and also the multiple-testing problem becomes more
serious.
Conclusion
Complex genetic diseases are believed to be caused by
multiple genetic and environmental factors working
together to produce susceptibility. The abundance of
SNPs (single nucleotide polymorphisms) together with
technologies that can measure hundreds of thousands of
SNPs across the genome make genome-wide association
studies feasible. New statistical methods that can deal
with such large-scale studies are needed. Two-stage
approaches, where the first stage is used to select promis-
ing markers using single-locus methods followed by a sec-
ond stage where multi-locus methods can be used, are
likely to be very useful.
In this report, we presented a simulation study to compare
two two-stage approaches: the conditional and the simul-
taneous approach. Our results suggest that the condi-
tional approach is more robust and performs generally
better over a range of disease models when compared with
the simultaneous approach. In particular, the conditional
approach succeeds in detecting weaker loci that have
strong interaction with more obvious loci (that are easy to
detect), whereas the simultaneous approach is not power-
ful in this realistic situation. Hence the two-stage condi-
tional approach is expected to be more powerful than the
simultaneous approach when applied to genome-wide
association studies.
Table 3: Multiplicative Model. Odds of disease for the multiplicative disease model.
Model 3
bb Bb BB
aa ααα
Aa αα (1 + θ) α(1 + θ)2
AA αα (1 + θ)2 α(1 + θ)4
Table 2: Missing Lethal Genotype Model. Odds of disease for the missing lethal genotype disease model.
Model 2
bb Bb BB
aa αα 2α(1 + θ)
Aa αα (1 + θ) α
AA 2α(1 + θ) ααBMC Genetics 2006, 7:39 http://www.biomedcentral.com/1471-2156/7/39
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Threshold Model Figure 2
Threshold Model. Comparison of the conditional approach with the simultaneous approach for the two-locus threshold dis-
ease model. θ = 2.5. Each picture corresponds to a specific combination of MAFs at the two disease loci as indicated above 
each plot.
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Threshold Model Figure 1
Threshold Model. Comparison of the conditional approach with the simultaneous approach for the two-locus threshold dis-
ease model. θ = 1.5. Each picture corresponds to a specific combination of MAFs at the two disease loci as indicated above 
each plot.
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thods
We now present the details of our procedure to compute
power for the two approaches: the simultaneous approach
and the conditional approach. Both methods are based on
the following two-stage algorithm:
Stage 1
A locus-by-locus search is performed and those markers
significant at a certain (marker-wise) level α are selected:
P( >  kα) = α (*)
We call this set of markers S (for selected) and the entire
set of markers M.
Stage 2
For each pair of loci (l, m) (for the simultaneousapproach
both l  and  m  are from S, whereas for the conditional
approach l ∈ S and m ∈ M) we fit the full logistic regres-
sion model (main effects and interaction).
The power to detect both disease loci with the simultane-
ous approach at a genome-wide error rate of 0.05 is:
Powers = P(detect both disease loci at (genome-wide) α =
0.05)
= P(detect both disease loci in Stage 1 at a certain level)
·  P(full model significant in Stage 2|both disease loci
detected in Stage 1)
Similarly for the conditional approach we have:
Powerc = P(detect both disease loci at (genome-wide) α =
0.05)
= P(detect ≥ 1 disease locus in Stage 1 at a certain level)
· P(full model significant in Stage 2| ≥ 1 disease locus
detected in Stage 1)
χ2
2
Missing Lethal Genotype Model Figure 3
Missing Lethal Genotype Model. Comparison of the conditional approach with the simultaneous approach for the two-
locus missing lethal genotype disease model. θ = 1.5. Each picture corresponds to a specific combination of MAFs at the two 
disease loci as indicated above each plot.
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The joint probability, P(detect both disease loci in Stage 1
at a certain level), can be estimated by the product of the
individual probabilities, i.e.
P(detect both disease loci in Stage 1 at a certain level) ≈
≈ P(detect locus 1 in Stage 1) · P(detect locus 2 in Stage
1).   (1)
This also implies that:
P(detect ≥ 1 disease locus in Stage 1 at a certainlevel) ≈
≈ P(detect locus 1 in Stage 1) + P(detect locus 2 in Stage 1)
- P(detect locus 1 in Stage 1) · P(detect locus 2 in Stage 1)
Note
The approximate equal sign in (1) is due to the fact that
the data are simulated under epistatic disease models,
where the ability to detect a disease locus is dependent not
only on the relative risk of that locus, but also on the rel-
ative risk of the other disease locus as well. The two-locus
interaction multiplicative and threshold models are syner-
glstic epistatic models where the correlation of the relative
risks at the two loci is positive; the missing lethal genotype
model is an antagonistic epistatic model, where the corre-
lation is negative. However, the magnitude of the mutual
information of the relative risks at the two loci is very
small in the simulated disease models.
For Stage 2, when we compute the power to find the full
model significant, we use a modified statistic to correct for
the fact that the markers in S were selected in Stage 1. We
make the same correction as in Marchini et al. [2]; namely,
if we denote by R(l,m) the log-likelihood ratio statistic in
Stage 2, we modify it as follows:
Simultaneous approach:   = R(l,m) - 2 · kα
Conditional approach:   = R(l,m)  -  kα  where  kα  is
defined as in (*).
′ R lm (, )
′ R lm (, )
Missing Lethal Genotype Model Figure 4
Missing Lethal Genotype Model. Comparison of the conditional approach with the simultaneous approach for the two-
locus missing lethal genotype disease model. θ = 2.5. Each picture corresponds to a specific combination of MAFs at the two 
disease loci as indicated above each plot.
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This correction is based on the following facts: R(l,m) ≥ Rl + Rm
Multiplicative Model Figure 6
Multiplicative Model. Comparison of the conditional approach with the simultaneous approach for the two-locus multiplica-
tive disease model. θ = 2.5. Each picture corresponds to a specific combination of MAFs at the two disease loci as indicated 
above each plot.
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Multiplicative Model. Comparison of the conditional approach with the simultaneous approach for the two-locus multiplica-
tive disease model. θ = 1.5. Each picture corresponds to a specific combination of MAFs at the two disease loci as indicated 
above each plot.
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where Rl is the log-likelihood ratio statistic for the model
with only locus l. Also for the conditional approach we
only know that Rl (l ∈ S) is greater than kα, whereas for the
simultaneous approach both Rl and Rm are greater than kα.
Three-locus Threshold Model Figure 8
Three-locus Threshold Model. Comparison of the conditional approach with the simultaneous approach for the three-
locus threshold disease model. θ = 5.0. Each picture corresponds to a specific combination of MAFs at the three disease loci as 
indicated above each plot.
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Three-locus Threshold Model Figure 7
Three-locus Threshold Model. Comparison of the conditional approach with the simultaneous approach for the three-
locus threshold disease model. θ = 2.5. Each picture corresponds to a specific combination of MAFs at the three disease loci as 
indicated above each plot.
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For Stage 2, we use a Bonferroni correction to achieve a
genome-wide error rate of at most 0.05. More exactly, for
the simultaneous approach the total number of tests in
Stage 2 is  , where αs is the cutoff used in Stage 1 and
L  is the total number of markers. For the conditional
approach the total number of tests in Stage 2 is αcL(L -
αcL) +  , where αc is the cutoff used in Stage 1 of the
conditional method.
The approach for the three-locus models is similar.
Stage 1
A locus-by-locus search is performed and those markers
significant at a certain level α are selected:
P( >  kα) = α
We call this set of markers S (for selected) and the entire
set of markers M.
Stage 2
For each triple of loci (l,  m,  n) (for the simultaneous
approach all l, m and n are from S, whereas for the condi-
tional approach l ∈ S, m ∈ M and n ∈ M) we fit the full
logistic regression model (main effects and interaction).
The power computations are similar to those above, hence
we omit the details.
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